Tellgen, March 18, 2023, Shanghai
As spring turns and warmth arrives, on March 17th, the “20th Anniversary Forum on the Development of Flow Fluorescence Technology” hosted by Tellgen was successfully held in Beijing, marking the first stop of the annual event. Accompanied by the green tiles and bricks of the ancient capital, the chirping birds welcomed the resonance of the world!
For two decades, we have worked together to create a better future. Flow fluorescence is representative of high-throughput technology, and as a pioneer in flow fluorescence technology in China, Tellgen has gone through 20 years of continuous research and development, updates, and iterations, achieving full automation of immune detection projects based on flow fluorescence technology. Now, nearly 70 projects such as tumor markers, autoantibodies, and ToRCH can be carried out. Through the “20th Anniversary Forum on the Development of Flow Fluorescence Technology,” Tellgen joined forces with many industry leaders and experts to gather wisdom and insights around the development and application of flow fluorescence technology, allowing more innovative achievements to emerge and comprehensively promoting forward-looking scientific research, medical transformation, and industrial transformation.
Over 20 years ago, one of the main problems faced by clinical laboratories was how to achieve a multi-indicator, quantitative detection process. It just so happened that flow fluorescence high-throughput joint testing characteristics met this demand. In the selection of development projects, we also combined China’s national conditions and technical characteristics, selecting tumor markers and HPV as the main breakthroughs. These two products are currently the main application scenarios of flow fluorescence in clinical laboratory testing. After 20 years of research and development, Tellgen has continuously innovated, from manual operation to semi-automatic, and finally achieved full automation of flow fluorescence immunoassay. The stability of the detection platform is also constantly improving. Currently, the latest generation of flow fluorescence immunoassay analyzers TESMI F4000 launched by Tellgen has developed nearly 70 analytes projects such as tumor markers, autoantibody spectra, ToRCH, quantitative occult blood, and liver fibrosis, which can help clinical laboratories to efficiently complete daily testing work. Not only that, Tellgen has also connected flow fluorescence and chemiluminescence platforms, and launched the ImmunDuo 2.0 Immunology Twin Island, TLA T6 and T8 lines, further expanding the application scenarios of flow fluorescence and making flow fluorescence technology more effective in joint testing.
Autoantibodies have clinical significance in the diagnosis, treatment monitoring, disease assessment, prognosis judgment, early warning, and prevention of autoimmune diseases. Professor Li emphasized the predictive value of autoantibodies in autoimmune diseases from the perspective of medical treatment before disease. Due to the complexity and diversity of autoantibodies, multiple autoantibodies need to be tested simultaneously for comprehensive analysis of autoimmune diseases. Therefore, a fast, good, and cost-effective technology is urgently needed to solve the current pain points of autoantibody detection in medical laboratories, such as slow speed, manual operation, and qualitative results. The advantages of flow fluorescence technology, such as high-throughput, quantitative detection, automation, and cost control, can provide better solutions for clinical laboratories and are the development trend of autoimmune medical testing.
Malignant tumors are one of the leading causes of death among residents in China, and early diagnosis and treatment of cancer are crucial. Although there are more and more early screening technologies and methods for tumors in recent years, serum-based tumor markers are still one of the classic solutions. Based on the characteristics of the incidence and mortality rates of cancer among Chinese residents, Aikang Group has selected more than ten tumor markers from numerous tumor markers, which are divided into TM12 for men and women, basically covering the common malignant tumors in China. In addition, as Aikang Group is a leading medical examination service provider in China, the screening of tumor markers has been gradually integrated into its physical examination products, providing more comprehensive cancer screening services for the public.
Speech by Vice President Wang Zhaohui, Aikang Group
Moderator Professor Yan Cunling, Peking University First Hospital
Moderator Professor Wang Yajie, Beijing Ditan Hospital, Capital Medical University
Speech by Professor Li Yongzhe, Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences
Speech by guest speaker Professor Wang Peichang, Capital Medical University Xuanwu Hospital
Speech by guest speaker Professor Toru Suzuki, University of Leicester, UK/Tokyo University, Japan
Speech by guest speaker Professor Yan Guangtao, Chinese PLA General Hospital
Speech by Yao Jian’er, Chairman of Tellgen Corporation